Summit (TM) 2.0 is a CSF-based liquid biopsy assay designed to enable comprehensive genomic profiling for characterization of CNS tumors. CNS malignancies present unique diagnostic challenges, as ...
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...
St. Louis, Nov. 15, 2005 -- A combination of brain scanning with a new imaging agent and cerebrospinal fluid (CSF) analysis has left neuroscientists encouraged that they may finally be moving toward ...
Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But findings from a team at the University of Michigan Rogel Cancer Center, led by Carl Koschmann, ...
Tailored Approaches in the Treatment of Patients With Colorectal Cancer Harboring Tropomyosin Receptor Kinase Fusion and Microsatellite Instability-High: A Case Report and Literature Review ...
Researchers found that individuals have distinct baseline levels of brain-derived proteins in cerebrospinal fluid, masking ...
Protein appears in nearly all body tissues, along with your enzymes, blood, and cerebrospinal fluid (CSF). Healthy CSF has a low amount of protein. If you show symptoms of an infection or nervous ...
Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But new findings suggest a new method could provide additional data about tumor markers before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results